ACRS News and Press, Aclaris Therapeutics Inc. From 01/19/21

Tenax Therapeutics, Inc. (TENX) +70% after announcing acquisition of PH Precision Med.Aclaris Therapeutics (ACRS) +66% on positive data from mid-stage rheumatoid arthritis.Minerva Neurosciences (NERV) +42% on announcing sale of Seltorexant Royalty for up to $155M.China Natural ...

Aclaris Therapeutics (ACRS) shares up ~62% premarket after it announces positive preliminary top-line results from a 12-week, Phase 2a clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, in subjects with moderate to severe r...

Durable Clinical Activity over 12 Weeks was Demonstrated Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid Arthritis ATI-450, an Investigational Oral MK2 Inhibitor, was Generally Well Tolerated ...

The Q4 earnings season cranks up with Procter & Gamble (PG), Netflix (NFLX) and Intel (INTC) some of the more intriguing names to spill numbers. It is week two of trading for Poshmark (POSH) and Petco (WOOF) after huge first day gains were pared a bit on Friday. The economic calendar brin...

Gainers: Nxt-ID (NXTD) +50%.Diginex (EQOS) +48%.Aethlon Medical (AEMD) +40%.MIND Technology (MIND) +27%.Aclaris Therapeutics (ACRS) +24%.Tilray (TLRY) +23%.MiMedx Group (MDXG) +22%.Amyris (AMRS) +21%.Drive Shack (DS) +20%.Marathon Patent Group (MARA) +19%.Losers: Concord Medical Services...

Gainers: Aethlon Medical (AEMD) +47%. Aclaris Therapeutics (ACRS) +32%. Tilray (TLRY) +23%. MiMedx Group (MDXG) +23%. Sio Gene Therapies (SIOX) +21%.Losers: Concord Medical Services Holdings (CCM) -43%. BioLineRx (BLRX) -30%. vTv Therapeutics (VTVT) -22%. Sensus Healthcare (SRTS) -1...

New Scientific Advisory Board of Immuno-Inflammatory Experts Preliminary Topline Data for the ATI-450-RA-201 Trial Expected in January 2021 WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical...

WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at th...

Aclaris Therapeutics (ACRS): Q3 GAAP EPS of -$0.25 beats by $0.05.Revenue of $1.4M (+42.9% Y/Y) misses by $0.04M.Press Release For further details see: Aclaris Therapeutics EPS beats by $0.05, misses on revenue

First Subject Dosed in Phase 2a Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis Initiated Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, for the Treatment of Cr...